» Articles » PMID: 15864097

Recent Developments in Tuberculosis Vaccines

Overview
Date 2005 May 3
PMID 15864097
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: The aim is to review findings related to the use of Bacille Calmette-Guerin (BCG) vaccine, focusing on its limitations and benefits in controlling tuberculosis (TB). Some new TB vaccines, which have entered or are expected to enter clinical trials, are highlighted.

Recent Findings: BCG is currently the only available vaccine against TB, and is widely administered within the World Health Organization Expanded Programme for Immunization. Several trials have shown that the protective efficacy of BCG varies between different populations. Recently, a 60-year follow-up study of American Indians reported the long-term efficacy of BCG to be 52%. The reasons for the low efficacy of the BCG vaccine may be generic differences in the BCG strains, differences in immunological properties of study populations or exposure to environmental factors such as mycobacteria. The low efficacy of the BCG vaccine has encouraged the search for a new vaccine. Among new vaccine candidates are live attenuated Mycobacterium tuberculosis vaccines, recombinant BCG, DNA vaccines, subunit vaccines and fusion proteins with novel adjuvants and delivery systems.

Summary: Today, most of the world's population is vaccinated with BCG. It is generally accepted that BCG protects against childhood TB but this immunity wanes with age, resulting in no or insufficient protection against TB. Using modern techniques, several research groups have developed more than 200 new vaccine candidates. Some of these vaccines are now in clinical trials. The clinical evaluation of these new vaccines should be designed to cover a heterogeneous population with great variation in immune responses.

Citing Articles

The BCG vaccine, advantages, and disadvantages of introducing new generation vaccines against .

Mahdizade Ari M, Beig M, Sholeh M, Khoshmirsafa M Clin Exp Vaccine Res. 2024; 13(3):184-201.

PMID: 39144128 PMC: 11319110. DOI: 10.7774/cevr.2024.13.3.184.


Effect of glycosylation on the affinity of the MTB protein Ag85B for specific antibodies: towards the design of a dual-acting vaccine against tuberculosis.

Bernardini R, Tengattini S, Li Z, Piubelli L, Bavaro T, Modolea A Biol Direct. 2024; 19(1):11.

PMID: 38268026 PMC: 10809592. DOI: 10.1186/s13062-024-00454-5.


Heterologous Boosting With -Based Recombinant Strains in BCG-Primed Mice Improved Protection Against Pulmonary Mycobacterial Infection.

Liu S, Tian S, Zhang Y, Tang T, Zeng J, Fan X Front Immunol. 2020; 11:2036.

PMID: 32983151 PMC: 7492678. DOI: 10.3389/fimmu.2020.02036.


Current trends in tuberculosis vaccine.

Soundarya J, Ranganathan U, Tripathy S Med J Armed Forces India. 2019; 75(1):18-24.

PMID: 30705473 PMC: 6349622. DOI: 10.1016/j.mjafi.2018.12.013.


How reliable is online diffusion of medical information targeting patients and families?.

Xavier-Elsas P, Bastos S, Ignez C Gaspar-Elsas M World J Exp Med. 2015; 5(4):244-50.

PMID: 26618111 PMC: 4655254. DOI: 10.5493/wjem.v5.i4.244.